28 related articles for article (PubMed ID: 30711936)
1. Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.
McCorkle JR; Gorski JW; Liu J; Riggs MB; McDowell AB; Lin N; Wang C; Ueland FR; Kolesar JM
PLoS One; 2021; 16(8):e0254205. PubMed ID: 34347777
[TBL] [Abstract][Full Text] [Related]
2. Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein.
Stordal B; Hamon M; McEneaney V; Roche S; Gillet JP; O'Leary JJ; Gottesman M; Clynes M
PLoS One; 2012; 7(7):e40717. PubMed ID: 22792399
[TBL] [Abstract][Full Text] [Related]
3. AS602801 treatment suppresses breast cancer metastasis to the brain by interfering with gap-junction communication by regulating Cx43 expression.
Yang Z; Yang L; Zhang J; Qian C; Zhao Y
Drug Dev Res; 2024 Feb; 85(1):e22124. PubMed ID: 37859299
[TBL] [Abstract][Full Text] [Related]
4. Cysteine allows ovarian cancer cells to adapt to hypoxia and to escape from carboplatin cytotoxicity.
Nunes SC; Ramos C; Lopes-Coelho F; Sequeira CO; Silva F; Gouveia-Fernandes S; Rodrigues A; Guimarães A; Silveira M; Abreu S; Santo VE; Brito C; Félix A; Pereira SA; Serpa J
Sci Rep; 2018 Jun; 8(1):9513. PubMed ID: 29934500
[TBL] [Abstract][Full Text] [Related]
5. ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells.
Bergonzini C; Gregori A; Hagens TMS; van der Noord VE; van de Water B; Zweemer AJM; Coban B; Capula M; Mantini G; Botto A; Finamore F; Garajova I; McDonnell LA; Schmidt T; Giovannetti E; Danen EHJ
J Exp Clin Cancer Res; 2024 Jan; 43(1):4. PubMed ID: 38163893
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of multidrug resistance to chemotherapy mediated by P‑glycoprotein (Review).
Tian Y; Lei Y; Wang Y; Lai J; Wang J; Xia F
Int J Oncol; 2023 Nov; 63(5):. PubMed ID: 37654171
[TBL] [Abstract][Full Text] [Related]
7. Role of protein phosphorylation in cell signaling, disease, and the intervention therapy.
Pang K; Wang W; Qin JX; Shi ZD; Hao L; Ma YY; Xu H; Wu ZX; Pan D; Chen ZS; Han CH
MedComm (2020); 2022 Dec; 3(4):e175. PubMed ID: 36349142
[TBL] [Abstract][Full Text] [Related]
8. Lumiflavin Reduces Cisplatin Resistance in Cancer Stem-Like Cells of OVCAR-3 Cell Line by Inducing Differentiation.
Yang R; Liu B; Yang M; Xu F; Wu S; Zhao S
Front Oncol; 2022; 12():859275. PubMed ID: 35669418
[TBL] [Abstract][Full Text] [Related]
9. Teaching an old dog new tricks: reactivated developmental signaling pathways regulate ABCB1 and chemoresistance in cancer.
Lee WK; Frank T
Cancer Drug Resist; 2021; 4(2):424-452. PubMed ID: 35582031
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine Cooperates with Everolimus to Inhibit the Growth of and Sensitize Malignant Meningioma Cells to Apoptosis Induced by Navitoclax, an Inhibitor of Anti-Apoptotic BCL-2 Family Proteins.
Yamamoto M; Suzuki S; Togashi K; Sugai A; Okada M; Kitanaka C
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406478
[TBL] [Abstract][Full Text] [Related]
11. Hedgehog-Gli2 Signaling Promotes Chemoresistance in Ovarian Cancer Cells by Regulating MDR1.
Wang Q; Wei X; Hu L; Zhuang L; Zhang H; Chen Q
Front Oncol; 2021; 11():794959. PubMed ID: 35059317
[TBL] [Abstract][Full Text] [Related]
12. Emerging Importance of Survivin in Stem Cells and Cancer: the Development of New Cancer Therapeutics.
Warrier NM; Agarwal P; Kumar P
Stem Cell Rev Rep; 2020 Oct; 16(5):828-852. PubMed ID: 32691369
[TBL] [Abstract][Full Text] [Related]
13. Hsa_circ_0002483 inhibited the progression and enhanced the Taxol sensitivity of non-small cell lung cancer by targeting miR-182-5p.
Li X; Yang B; Ren H; Xiao T; Zhang L; Li L; Li M; Wang X; Zhou H; Zhang W
Cell Death Dis; 2019 Dec; 10(12):953. PubMed ID: 31844042
[TBL] [Abstract][Full Text] [Related]
14. Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction.
Suzuki S; Yamamoto M; Sanomachi T; Togashi K; Sugai A; Seino S; Yoshioka T; Kitanaka C; Okada M
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31284441
[TBL] [Abstract][Full Text] [Related]
15. AS602801 Sensitizes Ovarian Cancer Stem Cells to Paclitaxel by Down-regulating MDR1.
Yamamoto M; Suzuki S; Togashi K; Sanomachi T; Seino S; Kitanaka C; Okada M
Anticancer Res; 2019 Feb; 39(2):609-617. PubMed ID: 30711936
[TBL] [Abstract][Full Text] [Related]
16. AS602801, an Anticancer Stem Cell Candidate Drug, Reduces Survivin Expression and Sensitizes A2780 Ovarian Cancer Stem Cells to Carboplatin and Paclitaxel.
Yamamoto M; Suzuki S; Togashi K; Sanomachi T; Seino S; Kitanaka C; Okada M
Anticancer Res; 2018 Dec; 38(12):6699-6706. PubMed ID: 30504379
[TBL] [Abstract][Full Text] [Related]
17. PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer.
Risnayanti C; Jang YS; Lee J; Ahn HJ
Sci Rep; 2018 May; 8(1):7498. PubMed ID: 29760419
[TBL] [Abstract][Full Text] [Related]
18. A Small-molecule Kinase Inhibitor, CEP-1347, Inhibits Survivin Expression and Sensitizes Ovarian Cancer Stem Cells to Paclitaxel.
Togashi K; Okada M; Yamamoto M; Suzuki S; Sanomachi T; Seino S; Yamashita H; Kitanaka C
Anticancer Res; 2018 Aug; 38(8):4535-4542. PubMed ID: 30061219
[TBL] [Abstract][Full Text] [Related]
19. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
